To show the feasibility, oncological and functional outcomes of neurovascular bundle (NVB) preservation during salvage robot-assisted radical prostatectomy (RARP).
Introduction
Prostate cancer (PCa) is the most prevalent visceral malignancy in US men [1] . According to data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry, 27.9% of men choose non-surgical treatments as primary therapy for localized PCa [2] . It has been shown that up to 72% of patients with increasing PSA levels after radiation therapy will have locally recurrent disease. [3] [4] [5] . Recently, it has been reported that 92% of men with biochemical recurrence after radiation therapy will receive systemic androgen deprivation therapy, while only 2% will receive potentially curative salvage radical prostatectomy (RP) [6] . In patients with localized recurrent PCa, a biochemical recurrence-free survival rate of 48% and a metastasis-free survival rate of 83% at 5 years after salvage RP have been documented in a large multi-institutional study [7] . Despite this proportion of cancer control, few patients choose this therapy because, historically, open salvage RP has been associated with a high complication rate and poor functional outcomes. The loss of dissection planes as a result of ionizing radiation or other previous treatments makes salvage RP a very technically challenging procedure. While there has been a decrease in operative complications in more recent reports, functional outcomes continue to be a major concern [8] because high rates of urinary incontinence (up to 67%) and erectile dysfunction in virtually all patients have been described in the literature [9] [10] [11] .
Recently, salvage robot-assisted RP (RARP) has emerged as an alternative to the open approach for these patients. These studies are relatively small with short follow-ups, but they suggest that salvage RARP is a feasible treatment option for select patients with recurrent PCa after primary therapy, and that it is associated with equivalent oncological outcomes to and shorter convalescence than the open approach. Complication rates seem to be better in salvage RARP series, but there is minimal assessment of functional outcomes in the literature [12] [13] [14] [15] [16] [17] . Furthermore, few of these studies reported performing neurovascular bundle (NVB) preservation during salvage RARP because of the altered pelvic anatomy and loss of tissue planes in patients undergoing this surgery.
The primary objectives of the present study were to analyse the feasibility of NVB preservation during salvage RARP and to evaluate its impact on functional outcomes, especially on the recovery of erectile function. The secondary objective was to assess the oncological outcomes in this setting.
Patients and Methods

Patient Population and Data Collection
After obtaining institutional review board approval, we conducted a study between January 2008 and March 2016 in a total of 6654 consecutive patients who underwent RARP for localized PCa, performed by one single surgeon (V.P) who had experience of >2000 RARP procedures. Among those patients, 80 underwent salvage RARP because of local recurrence after primary treatment (radiation therapy [63 patients] or ablative treatments [17 patients]). All of these patients had confirmation of positive biopsy and negative CT and bone scan. The quality of NVB preservation was graded by the surgeon prospectively at the termination of the salvage RARP using a 1-5 scoring system (1 = 0%, 2 < 50%, 3 = 50%, 4 = 75% and 5 ≥ 95%) in each side of the prostate, as described previously [18] . Data on overall NVB preservation were obtained using the mean of both side's percentages. To perform the descriptive and comparative analysis in terms of NVB preservation, these patients were categorized into two groups depending on the degree of nerve-sparing (NS) performed: those patients with ≥50% overall NVB preservation were included in the 'good-NS' group (43 patients), and those with <50% of overall NVB preservation were included in the 'poor-NS' group (37 patients).
Primary outcome measures in the two groups included: preoperative Sexual Health Inventory for Men (SHIM) score and AUA symptom scores; body mass index (BMI); Charlson comorbidity score; PSA; primary treatment; operating time; estimated blood loss; NS degree and approach; and complications (intra-operative and postoperative). All data variables were collected and entered in a prospective fashion. Morbidity was reported using Clavien-Dindo classification.
Oncological results were reported in terms of biochemical failure (BCF), comprising biochemical recurrence (defined by two consecutive PSA values >0.2 ng/mL and rising) and PSA persistence (defined as PSA values >0.2 ng/mL at 6 weeks after salvage RARP). Functional (potency) results were collected by clinical assessment or by telephone interview. Potency was defined as the ability to achieve a successful erection with penetration >50% of the time (with or without the use of oral phosphodiesterase-5 inhibitors). Patients having intercourse dependent only on penile injection, vacuum erection device or transurethral alprostadil were not considered potent.
Full continence was defined as 0 pads/day and 0-2 pad-use continence as ≤2 pads/day. Follow-up information was entered in the database at 6 weeks, 3, 6, 9, 12, 18 months and at 1 year intervals.
Surgical Technique for Nerve-Sparing in Salvage Robot-Assisted Radical Prostatectomy All procedures were transperitoneal and used the six-port technique with the DaVinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA). A pelvic lymph node dissection was performed in all the patients during salvage RARP.
The RARP and salvage RARP steps are similar, but some precautions need to be taken to minimize morbidity, especially in the steps described previously by our group [19] . The specific procedures that we use during NS in salvage RARP to maximize functional results are described below.
adhesions and fibrotic tissue, the anterograde approach is preferred so as to achieve better visualization and control of the structures, maximizing safety and functional outcomes.
Endopelvic Fascia
Dissection secondary adhesion and vessel injury are common in the salvage RARP setting, particularly after radiation treatment, and may result in loss of planes or troublesome bleeding during endopelvic fascia dissection and in NVB injury at a very early step of salvage RARP (Fig. 1A) . Immediate haemostasis is therefore necessary as soon as bleeding is encountered to facilitate further visualization of the NVB. This step is particularly difficult in patients who have undergone proton beam radiation therapy.
Posterior Dissection
Unlike non-salvage procedures, the correct plane in posterior dissection can be difficult to identify because this tissue is usually replaced by fibrotic layers; thus, when using a retrograde NS approach, this step should be performed gently with the back of scissors, with no thermal energy, and sharp dissection should be reserved only for when resistant fibrotic adhesions are encountered.
At this point, we use instant toggling of the camera to obtain better visualization of the posterior plane and improve NVB preservation during the medial approach.
Lateral Neurovascular Bundle Dissection
In very few cases, NVB dissection is easy and does not differ much from standard RARP; however, most of the time the correct plane is difficult to find because of adhesion of the structures (Fig. 1B) or abnormal vascularization (Fig. 1C) after the primary treatment, so it is very important to perform a blunt NVB dissection to preserve the nerves.
In the most difficult cases, severe fibrosis can be seen during the NVB dissection (Fig. 1D ). In such cases, it is necessary to use sharp dissection and it is very difficult to perform a full NS procedure.
Apical Neurovascular Bundle Dissection
In the salvage setting, it is essential to ligate the dorsal vein complex firmly before division to avoid back bleeding, to facilitate the apical dissection and section of the urethra, and to obtain the maximum length of urethra so as to facilitate the anastomosis and improve continence. The apical NVB runs parallel at this point, so it is important to perform a gentle dissection, avoiding excessive use of the thermal energy, to preserve the distal NVB fibres (Fig. 1E) . In the present series, this step was especially difficult in patients who underwent brachytherapy.
When a full NS procedure is possible in salvage RARP, the final view of NVB is very similar to that obtained when using the standard RARP procedure (Fig. 1F ).
Statistical Analysis
Categorical data were reported as counts and percentages. Normally distributed continuous variables were expressed as mean and SD values, and median with interquartile range was used in non-normally distributed continuous variables.
Two-sample t-tests were used to test the equality of means in normal continuous variables, the Mann-Whitney U-test was used for non-normal continuous variable, and the chi-squared test was used for categorical data analysis. The Kaplan-Meier method and regression models were used to identify survival estimations and predictors of potency, continence and biochemical failure. P values < 0.05 were considered statistically significant. SPSS software v. 22.0 (SPSS Inc., Chicago, IL, USA) was used to perform the statistical analysis.
Results
Preoperative and Demographic Data
Preoperative, clinical and demographic data comparisons between the good-NS group (n = 43) and the poor-NS group (n = 37) are summarized in Table S1 .
Mean age, BMI and Charlson comorbidity score did not differ between the groups (P > 0.05), while preoperative PSA was slightly higher, but not significantly so, in the poor-NS group (P = 0.054). A slightly higher proportion of patients was primarily treated with radiation in the good-NS group (86% vs 70.3%; P = 0.085) and there was a shorter time since primary treatment in that group (52.4 AE 47.9 vs 75.68 AE 48.6 months; P = 0.050). No differences in the proportion of previously potent patients (SHIM score ≥ 20) were observed between the good-NS group and the poor-NS group (32.6% vs 29.2%; P = 0.786), and all patients in both groups were continent before surgery.
Intra-operative and Postoperative Data
There were no differences in estimated blood loss, or total operating and console time between the groups (P > 0.05) as shown in Table S2 . By design, a higher overall degree of NS was observed in the good-NS group (66.4% vs 20.1%; P < 0.001) and the most frequent access was the retrograde approach. There were no intra-operative complications, and the overall incidence of postoperative complications was low in both the good-NS group (2.3%) and the poor-NS group (8.1%), with no significant differences between them (P = 0.237). All of these were minor complications according to Clavien-Dindo classification (one UTI and three lymphoceles with no drainage requirement). Radiological anastomotic leaks did not differ between groups (25.6% in the good-NS vs 35.1% in the poor-NS group; P = 0.353), and these were successfully managed with prolonged catheterization. A cystogram was performed every 7 days to confirm the healing of the anastomoses before catheter removal. No differences were observed in the length of hospital stay between groups; however, the poor-NS group required the catheter slightly longer than did the good-NS group (15.0 AE 10.8 days vs 11.95 AE 7.8 days; P = 0.147).
Pathological and Oncological Data
As shown in Table S3 , smaller tumours (1.4 AE 0.6 cm vs 1.7 AE 0.6 cm; P = 0.074) and lower volumes (14.8% AE 12.4 vs 21.3% AE 14.4; P = 0.037) were observed in the good-NS group compared with the poor-NS group. A slightly higher proportion of locally advanced PCa (≥pT3a) was observed in the poor-NS group (62.2%) compared with the good-NS group (44.2%; P = 0.108). There were no differences in positive surgical margins between the groups (14.3% in the good-NS group vs 25% in the poor-NS group; P = 0.231), and most of them were found in the apex in both groups (66% and 44%, respectively). No differences were found in terms of postoperative PSA levels (P = 0.612), androgen deprivation therapy requirement after salvage RARP (18.6% and 10.8%, P = 0.330) or BCF at 12 months between groups (26.1% and 29%, respectively, P = 0.801). The estimated BCFfree rate at 36 months was 69% and 66%, in the good-NS and poor-NS groups, respectively (P = 0.809; Fig 2) . In multivariate analysis, including NS, only Gleason score 8-10 was predictive for BCF (P = 0.009; Table S4 ).
Functional Data
Potency and continence rates at each follow-up are shown in Table 1 for both groups. Potency rates were higher in the good-NS group at all follow-ups than in the poor-NS group (P > 0.05). Potency at 12 months returned in 25.6% of patients in the good-NS group and in 4.3% of the poor-NS group (P = 0.036). In multivariate analysis, while good NS tended to be predictive of potency at 12 months, almost reaching significance (P = 0.065) ( cumulative incidence curve reporting the proportion of postoperatively potent patients showed a trend towards higher and faster potency in the good-NS group than in the poor-NS group (P = 0.086; Fig. 3 ).
While full continence rates were slightly, but not significantly, higher in the good-NS group than the poor-NS group at all follow-ups (P > 0.05), similar 0-2 pad-use continence rates (77.4% vs 78.3; P = 0.941) were observed in both groups at 12 months of follow-up. Similar timing and proportion of patients achieving full continence between groups were observed over the course of the study (P = 0.955; Fig. S1 ). In multivariate analysis, good NS tended to predict continence at 12 months (P = 0.119) but only non-radiation primary treatment was predictive of continence at 6 (P = 0.031) and 12 months (P = 0.033; Tables 3 and S5 ).
Discussion
Locally recurrent PCa after radiation therapy or other ablative techniques can have an aggressive natural history with poor outcomes [20] . Among the different approaches to treating recurrent PCa, salvage RP is only undergone by 2% of patients because, despite good cancer control outcomes, historically, salvage RP has been associated with significant morbidity and poor functional outcomes [9] [10] [11] .
Recently, salvage RARP has emerged as an alternative for these patients, with equivalent oncological outcomes and shorter convalescence than the open approach [21] , but functional outcomes continue to be a major concern and are minimally assessed in the literature. Postoperative potency is gaining importance because these patients are being diagnosed at younger ages, at earlier stages and with acceptable preoperative erectile function despite the primary treatment.
Only a few studies have reported postoperative erectile function after salvage RARP [13, 16, 22] , ranging from 20% to 29% among preoperative potent patients, but none of these studies analysed the impact and feasibility of NVB preservation in salvage RARP. To our knowledge, this is the first study describing the NS technique in this setting and the largest one reporting the recovery of potency in patients who underwent NS salvage RARP. Our group previously reported a retrospective study of 53 patients undergoing salvage RARP, comparing potency recovery between these patients and a matched 'non-salvage' RARP cohort. NS was performed in all patients who underwent RARP (33.9% full NS; 66.1% partial NS); however, no degree of NS was possible in seven patients undergoing salvage RARP (13.2%). A lower proportion of patients in the salvage RARP group were potent at 36 months than in the non-salvage group (31.5% vs 49.4%) [12] . Masterson et al. [23] assessed the feasibility of NVB preservation in the open salvage RP setting, performing NS in 29 of 100 patients (29%). Six of these 29 patients (20.7%) recovered potency after surgery, and time to potency was frequently prolonged, with three of six patients recovering potency 3 years or more after salvage RP.
In the present study, we assessed the impact of NVB preservation in terms of functional outcomes after salvage RARP, comparing those patients who underwent >50% NS (43) and those with <50% NS (37). Among 53 patients with 12 months of follow-up, 25.6% of patients in the good-NS group recovered potency vs only 4.3% with poor NS. As reported previously in the literature, recovery in terms of functional outcomes takes longer in salvage than in standard RARP [12] . In the present study, time to potency tended to be shorter in the good-NS group after salvage RARP. Most of these patients used phosphodiesterase-5 inhibitors at 12 months.
With regard to continence, Stephenson et al. [8] reported acceptable rates at 5 years after open salvage RP, with 39% of patients dry and 68% requiring ≤1 pad daily. In a more contemporary open series, a full continence rate of 64.2% of and a 0-1 pad-use rate of 80% were reported [24] . In the present series, overall continence rates 12 months after salvage RARP were high in both groups, but no substantial differences were seen between the groups, either in terms of full continence (58.1% in good-NS vs 47.8% in poor-NS group) or in terms of 0-2 pad-use rate (77.4% in the good-NS group vs 78.3% in the poor-NS group). The only factor predicting better continence was primary treatment received, with those patients who underwent non-radiation primary treatment having a higher probability of reaching continence It is remarkable that no differences in terms of oncological outcomes were observed regarding NVP preservation degree, with BCF-free survival being similar in the two groups.
Similarly to previous studies [22] , only a high Gleason score (8-10) was predictive of BCF in the present study. By contrast to other standard RARP studies, however, a lower positive surgical margin rate was observed in those patients who underwent NVB preservation [25] . This could be explained by the lower proportion of locally advanced PCa and lower tumour volumes in the good-NS group. These two factors probably influenced the ease of NVB release and final overall grade of NS during the salvage procedure; thus, a great proportion of patients are potential candidates for NS in salvage RARP, provided that surgical margins and oncological outcomes are not compromised in selected patients.
Preoperatively, we select patients for NS on the basis of previous erectile function and cancer features, so we tend to offer a higher grade of NVB preservation in younger patients with good preoperative sexual function and early stages of recurrent PCa. However, the ease of NVB release assessed intra-operatively was the most important factor regarding the final grade of NS in salvage RARP. From our point of view, that depends on the kind of primary treatment and stage of PCa, with salvage RARP being more difficult in patients who underwent radiation primary treatment, in particular proton beam radiation therapy, as well as in those with locally advanced recurrent disease. In other settings, NS is feasible, safe and offers hope to those patients with recurrent PCa interested in the recovery of erectile function after salvage RARP. Concerning all these factors, it should be noted that it is difficult to predict NS grade and further functional outcomes before salvage surgery, but all these factors allows the surgeon to advise future patients on their likely potency outcomes after salvage RARP. Despite the potential selection bias factors mentioned, no differences regarding potency were found between groups, either in the univariate analysis or in the multivariate analysis; instead, there was a clear trend predicting potency at 12 months in the multivariate analysis regarding type of NS.
Technically, the challenging parts of the salvage procedure were the posterior and the apical dissection. The planes were often significantly worse in patients with prior radiation therapy compared with ablative therapy. Proton beam radiation therapy was the most destructive, with lateral spread to the tissues beyond the prostate; proton therapy appeared to have the least focused energy and most collateral damage. Generally, the vesicourethral anastomosis was performed similarly to the non-salvage setting; a Van Velthoven vesicourethral anastomosis with a running suture (double needle, 2-0 quill, 16 cm 9 16 cm in length, half-circle 17-mm needle), with bladder neck reconstruction, an anterior suspension stitch, and posterior reconstruction was performed. In the last 19 patients of the cohort, a urinary bladder extracellular matrix scaffold was incorporated into the posterior aspect of the vesico-urethral anastomosis to decrease the rate of anastomotic leak in salvage RARP [26] .
The present study has some limitations. First, it was a retrospective analysis of prospectively collected data, and, as mentioned previously, there was potential selection bias. Second, the small number of patients in both groups limits the power of statistical analysis and the strength of its conclusions. Third, the outcomes obtained were from a high-volume centre with a highly experienced unique surgeon; the results might not be generalizable to a low-volume centre. Fourth, the assessment of potency or continence (including validated questionnaires and open interviews)
is not yet standardized, so discrepancy regarding the definition of potency before and after salvage RARP, together with the short follow-up available in this series (given the well-known delay in recovery of potency and continence in the salvage setting), may have had an effect on functional outcomes. Fifth, any conclusions with regard to oncological outcomes should be drawn with caution as the follow-up was short, at only 1-year.
In conclusion, to our knowledge, the present study is the largest to-date that specifically assesses potency and continence outcomes and the feasibility of NVB preservation in salvage RARP. Despite the relatively small number of patients, the findings of this study support the feasibility and safety of NVB preservation in select patients in a highvolume institution and the subsequent better recovery of adequate erections for intercourse, without compromising short-term oncological outcomes. These results offer hope to select patients who wish to receive curative treatment for locally recurrent PCa while preserving potency. The unique factor predicting continence after salvage RARP was primary treatment received, with better continence achieved in those patients who underwent ablative therapies.
Supporting Information
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